These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20024547)

  • 1. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked.
    von Lilienfeld-Toal M; Frank S; Leyendecker C; Feyler S; Jarmin S; Morgan R; Glasmacher A; Märten A; Schmidt-Wolf IG; Brossart P; Cook G
    Cancer Immunol Immunother; 2010 Jun; 59(6):829-39. PubMed ID: 20024547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered NK-cell compartment and dysfunctional NKG2D/NKG2D-ligand axis in patients with ataxia-telangiectasia.
    Desimio MG; Finocchi A; Di Matteo G; Di Cesare S; Giancotta C; Conti F; Chessa L; Piane M; Montin D; Dellepiane M; Rossi P; Cancrini C; Doria M
    Clin Immunol; 2021 Sep; 230():108802. PubMed ID: 34298181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
    Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
    BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.
    Crane CA; Han SJ; Barry JJ; Ahn BJ; Lanier LL; Parsa AT
    Neuro Oncol; 2010 Jan; 12(1):7-13. PubMed ID: 20150362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion.
    Lundholm M; Schröder M; Nagaeva O; Baranov V; Widmark A; Mincheva-Nilsson L; Wikström P
    PLoS One; 2014; 9(9):e108925. PubMed ID: 25268476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
    Zingoni A; Vulpis E; Cecere F; Amendola MG; Fuerst D; Saribekyan T; Achour A; Sandalova T; Nardone I; Peri A; Soriani A; Fionda C; Mariggiò E; Petrucci MT; Ricciardi MR; Mytilineos J; Cippitelli M; Cerboni C; Santoni A
    Front Immunol; 2018; 9():926. PubMed ID: 29765374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
    Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
    Front Immunol; 2018; 9():1282. PubMed ID: 29963042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NKG2D is a costimulatory receptor for human naive CD8+ T cells.
    Maasho K; Opoku-Anane J; Marusina AI; Coligan JE; Borrego F
    J Immunol; 2005 Apr; 174(8):4480-4. PubMed ID: 15814668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance.
    Vulpis E; Loconte L; Peri A; Molfetta R; Caracciolo G; Masuelli L; Tomaipitinca L; Peruzzi G; Petillo S; Petrucci MT; Fazio F; Simonelli L; Fionda C; Soriani A; Cerboni C; Cippitelli M; Paolini R; Bernardini G; Palmieri G; Santoni A; Zingoni A
    J Extracell Vesicles; 2022 Jan; 11(1):e12176. PubMed ID: 34973063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients.
    Dulphy N; Berrou J; Campillo JA; Bagot M; Bensussan A; Toubert A
    J Invest Dermatol; 2009 Feb; 129(2):359-64. PubMed ID: 18754036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.
    Cerboni C; Ardolino M; Santoni A; Zingoni A
    Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
    Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
    Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
    Ge X; Li CR; Yang J; Wang GB
    Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H; Kim J; Cosman D; Choi I
    Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients.
    Mou X; Zhou Y; Jiang P; Zhou T; Jiang Q; Xu C; Liu H; Zheng T; Yuan G; Zhang Y; Chen D; Mao C
    Sci Rep; 2014 Aug; 4():6138. PubMed ID: 25138242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human tumor-derived exosomes down-modulate NKG2D expression.
    Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
    J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity.
    Cao W; Xi X; Hao Z; Li W; Kong Y; Cui L; Ma C; Ba D; He W
    J Biol Chem; 2007 Jun; 282(26):18922-8. PubMed ID: 17470428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.